Effects of Holy-Comod and Tears Naturale Forte in Patients After Phaco+IOL
NCT ID: NCT02817191
Last Updated: 2016-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2016-06-30
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hylo-Comod
The patients used Hylo-Comod eye drop after phaco+IOL in this group.
Hylo-Comod eye drop
The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
Tears Naturale Forte
The patients used Tears Naturale Forte eye drop after phaco+IOL in this group.
Tears Naturale Forte eye drop
The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hylo-Comod eye drop
The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
Tears Naturale Forte eye drop
The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* classification of lens nucleus is LOCS Ⅱ
Exclusion Criteria
60 Years
72 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xingwu Zhong, MD PhD
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xingwu Zhong, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Zhongshan Ophthalmic Center, Sun Yat-sen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hainan Eye Hospital, Zhongshan Ophthalmic Center of Sun Yat-sen University
Haikou, Hainan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xingwu Zhong, MD,PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-005
Identifier Type: -
Identifier Source: org_study_id